Trial reportBritish journal of clinical pharmacology2017
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Trial report in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Trial
- Randomized Controlled Trial of the Gastrin/CCKCancer prevention research (Philadelphia, Pa.) · 2021Trial
- Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.Cellular and molecular gastroenterology and hepatology · 2020Trial
- Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.British journal of clinical pharmacology · 2017Trial
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Controversies in NEN: An ENETS position statement on the endoscopic management of localised gastric, duodenal and rectal neuroendocrine neoplasms.Journal of neuroendocrinology · 2025Review
- Proliferation-Based WHO Grading and Heterogeneous Gastrin Expression in Canine Gallbladder Neuroendocrine Tumors.Veterinary sciences · 2025Article
- Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.World journal of clinical oncology · 2025Article
- Rare epithelial gastric cancers: a review of the current treatment knowledge.Therapeutic advances in medical oncology · 2025Review
- Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute.Endocrine oncology (Bristol, England) · 2025Article
- Unraveling the Mysteries of Autoimmune Gastritis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Review
- Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.Life (Basel, Switzerland) · 2024Review
- Gastric neuroendocrine neoplasms.Nature reviews. Disease primers · 2024Review
- Autoimmune Atrophic Gastritis: A Clinical Review.Cancers · 2024Review
- Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?Medicina (Kaunas, Lithuania) · 2023Review
- Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study.Biomedicines · 2023Article
- Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.Endocrine · 2022Article
- Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms.World journal of gastrointestinal surgery · 2022Review
- New Developments in Gastric Neuroendocrine Neoplasms.Current oncology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsNetazepide, a gastrin/cholecystokinin 2 receptor antagonist, once daily for 12 weeks reduced the number of tumours and size of the largest one in 16 patients with autoimmune chronic atrophic gastritis (CAG), achlorhydria, hypergastrinaemia and multiple gastric neuroendocrine tumours (type 1 gastric NETs), and normalized circulating chromogranin A (CgA) produced by enterochromaffin-like cells, the source of the tumours. The aim was to assess whether longer-term netazepide treatment can eradicate type 1 gastric NETs.
methodsAfter a mean 14 months off netazepide, 13 of the 16 patients took it for another 52 weeks. Assessments were: gastroscopy; gene-transcript expression in corpus biopsies using quantitative polymerase chain reaction; blood CgA and gastrin concentrations; and safety assessments.
resultsWhile off-treatment, the number of tumours, the size of the largest one, and CgA all increased again. Netazepide for 52 weeks: cleared all tumours in 5 patients; cleared all but one tumour in one patient; reduced the number of tumours and size of the largest one in the other patients; normalized CgA in all patients; and reduced mRNA abundances of CgA and histidine decarboxylase in biopsies. Gastrin did not increase further, confirming that the patients had achlorhydria. Netazepide was safe and well tolerated.
conclusionsA gastrin/cholecystokinin 2 receptor antagonist is a potential medical and targeted treatment for type 1 gastric NETs, and an alternative to regular gastroscopy or surgery. Treatment should be continuous because the tumours will regrow if it is stopped. Progress can be monitored by CgA in blood or biomarkers in mucosal biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.